{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:09:46Z","timestamp":1789016986944,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008235","name":"University of Utah School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008235","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jlb.2026.100486","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:39:26Z","timestamp":1786750766000},"page":"100486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC)"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9735-6614","authenticated-orcid":false,"given":"Manish","family":"Kohli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-8369","authenticated-orcid":false,"given":"Aik Choon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Zaki","family":"Fadlullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anushka","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithra J.","family":"Mandrekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jlb.2026.100486_bib1","first-page":"308","article-title":"Cancer treatment and survivorship statistics, 2025","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jlb.2026.100486_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-025-01148-2","article-title":"A bayesian network meta-analysis of systemic treatments for metastatic castration-resistant prostate cancer in First- and subsequent lines","author":"Wosny","year":"2025","journal-title":"Targeted Oncol"},{"issue":"2","key":"10.1016\/j.jlb.2026.100486_bib3","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jlb.2026.100486_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.jlb.2026.100486_bib5","article-title":"Cabazitaxel versus abiraterone or enzalutamide for poor-prognosis metastatic castration-resistant prostate cancer after docetaxel: a phase 2 trial with a circulating tumor DNA analysis","author":"Parekh","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"15","key":"10.1016\/j.jlb.2026.100486_bib6","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1200\/JCO.22.02661","article-title":"External validation of a prognostic model of overall survival in men with chemotherapy-naive metastatic castration-resistant prostate cancer","volume":"41","author":"Halabi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jlb.2026.100486_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.18.01279","article-title":"Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel","volume":"37","author":"Halabi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jlb.2026.100486_bib8","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/jnci\/djt280","article-title":"Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy","volume":"105","author":"Halabi","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.jlb.2026.100486_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jlb.2026.100486_bib10","article-title":"Prognostic index model for progression-free survival in chemotherapy-naive metastatic castration-resistant prostate cancer treated with abiraterone acetate plus prednisone","author":"Ryan","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.jlb.2026.100486_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102728","article-title":"Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer","volume":"54","author":"Kohli","year":"2020","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.jlb.2026.100486_bib12","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1200\/PO.20.00424","article-title":"Plasma cell\u2013free DNA profiling of PTEN-PI3K-AKT pathway aberrations in metastatic castration-resistant prostate cancer","author":"Kwan","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jlb.2026.100486_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.eururo.2014.07.035","article-title":"Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer","volume":"67","author":"Huang","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jlb.2026.100486_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41391-018-0043-z","article-title":"Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients","volume":"21","author":"Kohli","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"19","key":"10.1016\/j.jlb.2026.100486_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194714","article-title":"Plasma copy number alteration-based prognostic and predictive multi-gene risk score in metastatic castration-resistant prostate cancer","volume":"14","author":"Huang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"312","key":"10.1016\/j.jlb.2026.100486_bib16","doi-asserted-by":"crossref","first-page":"312re10","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jlb.2026.100486_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkaf025","article-title":"Multi-gene risk score for prediction of clinical outcomes in treatment-naive metastatic castrate-resistant prostate cancer","volume":"9","author":"Fadlullah","year":"2025","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.jlb.2026.100486_bib18","article-title":"Pathogenic genomic alterations in circulating tumor DNA predict overall survival in men with metastatic castrate-resistant prostate cancer","author":"Halabi","year":"2025","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.jlb.2026.100486_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.urolonc.2025.07.034","article-title":"Liquid biopsy testing in urological cancers: focus on urine","volume":"43","author":"Pisapia","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.jlb.2026.100486_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100305","article-title":"Blood and urine-based biomarkers in prostate cancer: current advances, clinical applications, and future directions","volume":"9","author":"Crocetto","year":"2025","journal-title":"J Liq Biopsy"},{"issue":"5","key":"10.1016\/j.jlb.2026.100486_bib21","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"27","key":"10.1016\/j.jlb.2026.100486_bib22","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","article-title":"Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Bejar","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jlb.2026.100486_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jlb.2026.100486_bib24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024027540","article-title":"IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score","author":"Raddi","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.jlb.2026.100486_bib25","unstructured":"R: the R project for statistical computing.\" https:\/\/www.r-project.org\/(accessed."},{"key":"10.1016\/j.jlb.2026.100486_bib26","author":"Society"},{"key":"10.1016\/j.jlb.2026.100486_bib27","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jlb.2026.100486_bib28","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jlb.2026.100486_bib29","doi-asserted-by":"crossref","DOI":"10.1002\/bco2.455","article-title":"PARP inhibitor-based treatment in metastatic, castration-resistant prostate cancer (mCRPC): a systematic review and meta-analysis","volume":"6","author":"Roberto","year":"2025","journal-title":"BJUI Compass"},{"issue":"3","key":"10.1016\/j.jlb.2026.100486_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkag042","article-title":"Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer","volume":"10","author":"Kohli","year":"2026","journal-title":"JNCI Cancer Spectr"},{"issue":"25","key":"10.1016\/j.jlb.2026.100486_bib31","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jlb.2026.100486_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-Gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100486_bib33","article-title":"Multigene copy number alteration risk score biomarker-based enrichment study designs in metastatic castrate-resistant prostate cancer","volume":"8","author":"Jo","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.jlb.2026.100486_bib34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/annonc\/mdx689","article-title":"A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate-prednisone","volume":"29","author":"Wang","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jlb.2026.100486_bib35","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1158\/1541-7786.MCR-22-0099","article-title":"Molecular profile changes in patients with castrate-resistant prostate cancer Pre- and post-Abiraterone\/Prednisone treatment","volume":"20","author":"Sicotte","year":"2022","journal-title":"Mol Cancer Res"},{"issue":"1","key":"10.1016\/j.jlb.2026.100486_bib36","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jlb.2026.100486_bib37","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2307\/2529872","article-title":"Nonparametric estimation of lifetime and disease onset distributions from incomplete observations","volume":"38","author":"Dinse","year":"1982","journal-title":"Biometrics"},{"issue":"18","key":"10.1016\/j.jlb.2026.100486_bib38","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jlb.2026.100486_bib39","first-page":"859","article-title":"Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology","volume":"10","author":"Qin","year":"2013","journal-title":"M\u00e9d Sur"},{"issue":"5","key":"10.1016\/j.jlb.2026.100486_bib40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.jlb.2026.100486_bib41","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-Mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100486_bib42","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100486_bib43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jlb.2026.100486_bib44","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.jlb.2026.100486_bib45","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.jlb.2026.100486_bib46","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1200\/JCO.18.01731","article-title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jlb.2026.100486_bib47","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","article-title":"Final overall survival and molecular data associated with clinical outcomes in patients receiving ipatasertib and abiraterone in the phase 3 IPATential150 trial","volume":"87","author":"de Bono","year":"2025","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jlb.2026.100486_bib48","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-022-06580-w","article-title":"Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis","volume":"193","author":"Davey","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.jlb.2026.100486_bib49","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined Tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:43Z","timestamp":1789014583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426000329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":49,"alternative-id":["S2950195426000329"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100486","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC)","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100486"}}